I. A. Levashov

I. A. Levashov

Auto-generated profile, based on publicly available information

I. A. Levashov

Multidisciplinary Medical Center of the Central Bank of the Russian Federation, Moscow, Russia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VYV. A. Yarovaya
V. A. Yarovaya
ILI. A. Levashov
I. A. Levashov
AZAndrew R. Zaretsky
Andrew R. Zaretsky
LCL. V. Chudakova
L. V. Chudakova
VNV. V. Nazarova
V. V. Nazarova
AYA. A. Yarovoy
A. A. Yarovoy
Introduction. Molecular genetic testing is actively used for prognostication in patients with uveal melanoma (UM). Tissue for genetic analysis may be obtained either by surgical excision or through fine-needle aspiration biopsy (FNAB). Performing genetic testing and FNAB in each institution can differ in surgical techniques and laboratory methodologies.Aim. To present our own experience of performing FNAB-based molecular genetic testing for prognostication in patients with uveal melanoma.Materials and methods. Prognostic FNAB (n = 151) were combined with brachytherapy or stereotactic surgery. Genetic testing was performed by methods based on polymerase chain reaction (GNAQ, GNA11, EIF1AX and SF3B1 mutations) and fluorescence in situ hybridization (copy numbers of PPARG and MYC genes); cytology of FNAB material was also assessed.Results. Fine-needle aspiration biopsy material was informative in 91 % of cases. At the median follow-up of 36 months, 12 cases of distant metastases were detected. Occurrence of the assessed mutations and copy numbers were related to other representative studies. PPARG deletion was shown to be a significant prognostic factor for metastasis-free survival (p 0,01), which was demonstrated for the first time; EIF1AX and SF3B1 mutations, MYC amplification and cytological class were not shown to be significantly associated with survival in our study.Conclusion. FNAB-based molecular genetic testing for prognostication in patients with uveal melanoma was shown to be a reliable and highly informative approach. Some of the prognostic factors need to be evaluated further with longer follow-up.

15 January 2022 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
VYV. A. Yarovaya
V. A. Yarovaya
AYA. A. Yarovoy
A. A. Yarovoy
LCL. V. Chudakova
L. V. Chudakova
ILI. A. Levashov
I. A. Levashov
AZA. R. Zaretskiy
A. R. Zaretskiy
Introduction. Uveal melanoma ability to metastasize depends on a few prognostic factors. The genetic ones are considered to be the most significant. The role of disorders of the short arm of chromosome 8 (8p), as well as a combination of changes in 8p and the long arm of this chromosome (8q) in the development of metastatic lesions in this pathology remains insufficiently studied.The study objective – to evaluate the prognostic value of chromosome 8 abnormalities in patients with uveal melanoma.Materials and methods. We analyzed 2 retrospective groups of patients who underwent enucleation for uveal melanoma, statistically homogeneous in the main clinical parameters. Group 1 included patients without signs of metastases (n = 41) with an average follow-up period of 71 months, Group 2 included patients with detected metastases (n = 51) and an average follow-up period of 21 months Chromosome abnormalities were tested by multiplex ligation-dependent probe amplification.Results. Three- and five-year survival in patients with uveal melanoma without 8p deletion were 64 and 54 %, respectively; with 8p deletion significantly lower – 25 and 6 %, respectively. The same survival rates in patients with uveal melanoma with 8q amplification were 43 and 26 %, respectively, whereas in patients without 8q amplification they were significantly higher – 80 and 74 %, respectively. In patients with uveal melanoma harbouring both abnormalities, 3- and 5-year survival rates were 26 and 7 %, whereas isolated 8q amplification was associated with 47 and 35 % survival, respectively. These survival rates differ greatly and significantly: hazard ratio 3,26 (95 % confidence interval 1,86–5,69) and 6,89 (95 % confidence interval 2,67–17,73), respectively (р 0,0001).Conclusion. The findings support comprehensive evaluation of chromosome 8 abnormalities as a substantial part of uveal melanoma prognostication. 8q amplification, 8p deletion, combination of these abnormalities and its role in uveal melanoma malignity should be further discovered. Further research in this direction is needed.

6 September 2024 in Voprosy onkologii
Verified
Journal Article
Open access
ВЯВера Андреевна Яровая
Вера Андреевна Яровая
ИЛИлья Андреевич Левашов
Илья Андреевич Левашов
АЯАндрей Александрович Яровой
Андрей Александрович Яровой
Введение. Прогнозирование течения увеальной меланомы (УМ) подразумевает анализ клинических, морфологических и генетических особенностей опухоли — многочисленных и разнородных по своей природе факторов. Отсутствие единого прогностического подхода затрудняет стратификацию рисков метастазирования УМ как в клинической практике, так и при информировании пациента о прогнозе заболевания, что обуславливает актуальность в разработке собственного прогностической системы. Цель. Разработка комплексной системы индивидуального прогнозирования риска метастазирования УМ с учетом клинических, морфологических и молекулярно-генетических факторов. Материалы и методы. Всего были отобраны данные 202 пациентов c УМ. В качестве первичного метода лечения в 57 % случаев проводилась энуклеация (n = 115), в 43 % случаях (n = 83) — лучевая терапия. При органосохраняющем лечении материал для цитологического и молекулярно-генетического исследования был получен с помощью тонкоигольной аспирационной биопсии (ТИАБ). Оценивались ключевые клинические (размер и локализация опухоли, пол и возраст), морфологические (клеточный тип и инвазия в цилиарное тело) и молекулярно-генетические (мутации в генах EIF1AX, SF3B1, PPARG, MYC) факторы. Результаты. Средний срок наблюдения составил 42 мес. (медиана 35, min 1, max 182). В данный период было отмечено 78 случаев метастазирования (39 %). Были определены факторы, статистически значимо (p < 0,01) влияющие на риск метастазирования УМ: размер, локализация и клеточный тип опухоли, мутации в генах EIF1AX, PPARG, MYC. Выводы. Разработанная комплексная система прогнозирования риска метастазирования увеальной меланомы, учитывающая эти факторы, позволила стратифицировать риск метастазирования по баллам и выделить три достоверно различающихся между собой (p < 0,01) категории прогноза: «неблагоприятный», «средний» и «благоприятный». Система требует валидации на данных других пациентов с УМ.

4 July 2020 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
AYA. A. Yarovoy
A. A. Yarovoy
TUT. L. Ushakova
T. L. Ushakova
OGO. V. Golubeva
O. V. Golubeva
ILI. A. Levashov
I. A. Levashov
SMS. N. Mikhailova
S. N. Mikhailova
VPV. G. Polyakov
V. G. Polyakov
Relevance. Development and application of novel treatment methods for patients with retinoblastoma (Rb) is a great task since it may provide higher rates of eye salvage and reduce adverse effects of current therapy.Aim of the study was to represent the history of Rb eye-sparing treatment in Russia and worldwide through the one clinical case.Materials and methods. A child was treated by systemic chemotherapy, plaque brachytherapy using non-described techniques, cryotherapy and external beam radiotherapy. Intravitreal chemotherapy was approached for treatment of vitreous seeding. Vitreoretinal surgery with melphalan irrigation was successfully performed after failure of vitreous hemorrhage conservative treatment and parents’ refusal to indicated enucleation. The child died from CNS disseminated esthesioneuroblastoma.Results. The use of various treatment modalities helped to save the single eye.Conclusions. Intravitreal chemotherapy was introduced in Russia for the first time. Performed vitreoretinal surgery with melphalan irrigation was proved to be a safe and effective technique in case of vitreous hemorrhage in the eye with Rb. External beam therapy is associated with fatal second tumors development.

15 March 2024 in Malignant tumours
Verified
Journal Article
Open access
PDF file
VYV. А. Yarovaya
V. А. Yarovaya
AGAndrey Golanov
Andrey Golanov
VNV. V. Nazarova
V. V. Nazarova
АZА. R. Zaretskii
А. R. Zaretskii
ILI. А. Levashov
I. А. Levashov
АYА. А. Yarovoy
А. А. Yarovoy
To date, the issue of not only timely diagnosis and treatment of patients with uveal melanoma (UM), but also the prediction of this pathology remains relevant. The technology of fine needle aspiration biopsy (FNAB) makes it possible to assess the risk of developing metastatic disease using tumor specimen in patients undergoing organ-preserving treatment by cytological and molecular genetic testing in the primary intraocular lesion. Here we present a case of newly identified locally advanced (T3a) UM, outline the possibilities of organ-preserving treatment using Gamma Knife stereotactic radiosurgery, and also demonstrate the feasibility of conducting a comprehensive prognostic testing on FNAB material, including cytological and molecular genetic and morphological prognostic factors. The results of this testing have made it possible to recommend a more frequent surveillance monitoring regime for metastatic disease, which ultimately led to the early detection of UM liver metastases, followed by their successful treatment.

10 April 2025 in Лечащий врач
Verified
Journal Article
Closed access
ILI.A. Levashov
I.A. Levashov
DGD.B. Gorodetskiy
D.B. Gorodetskiy
Background. Medication support of cataract surgery is an integral part of it. The standard regimen of local therapy includes an antibiotic, a glucocorticosteroid, and a nonsteroidal anti-inflammatory drug. Each of the many nonsteroidal anti-inflammatory drugs has unique pharmacological properties, which determines the relevance of information on the choice of a drug from this group in the drug support of cataract surgery. Objective. The purpose of this study is to form an up-to-date understanding of nonsteroidal anti-inflammatory drugs in the drug support of the perioperative period of cataract surgery. The study was conducted in the format of a narrative review. The variety of topical nonsteroidal anti-inflammatory drugs used in ophthalmology is represented by diclofenac, ketorolac, bromfenac, indomethacin, and nepafenac. Differences in the chemical structure of the drugs determine the features of their pharmacodynamics and pharmacokinetics. A significant amount of evidence has accumulated in the literature in the form of results of randomized studies with a control group and experimental works indicating positive anti-inflammatory properties of nonsteroidal anti-inflammatory drugs used in the perioperative period of cataract surgery. Conclusion. The presented studies demonstrate that nepafenac exhibits significant pharmacodynamic properties for penetration into the anterior chamber of the eye, and also has an anti-inflammatory effect in the posterior segment of the eye against the background of local application, which determines the unique therapeutic potential of Apfecto. Apfecto is a cost-effective generic nepafenac produced with international quality standards.